Otonomy, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David M. Maggio
- Full Time Employees
- 51
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4796 Executive Drive San Diego CA United States of America 92121
- IPO Date
- Aug 13, 2014
- CIK
- 0001493566
- Website
- otonomy.com
- Similar Companies
- Business
- Otonomy, Inc. (OTIC) was a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics targeting diseases and disorders of the ear, including hearing loss, tinnitus, Meniere's disease, and neurotologic conditions. The company offered OTIPRIO (ciprofloxacin otic suspension) for pediatric use during tympanostomy tube placement surgery; OTO-104 and OTO-313, sustained-exposure formulations of steroids and gacyclidine, respectively, for Meniere's disease and tinnitus treatment in Phase II clinical trials; OTO-413, a brain-derived neurotrophic factor formulation for cochlear synaptopathy and speech-in-noise hearing difficulties; OTO-510, an otoprotectant to prevent cisplatin-induced ototoxicity; OTO-825, a gene therapy for congenital hearing loss developed in collaboration with Applied Genetic Technologies Corporation; and OTO-6XX for hair cell repair and regeneration in severe hearing loss. Otonomy leveraged proprietary drug delivery technology enabling sustained local administration to the inner and middle ear, protected by broad patent estates and license agreements with the University of California and DURECT Corporation. All operations focused on the United States market. Founded in 2008 and headquartered in San Diego, California, the company served healthcare professionals, patients, and researchers through clinical support, patient education programs, clinical trial participation opportunities, and collaborative research initiatives. In March 2023, Otonomy ceased operations by filing a certificate of dissolution with the State of Delaware, approved a liquidating distribution of $0.11 per share to stockholders of record as of March 27, 2023, closed stock transfer books, and instructed discontinuation of common stock transfers, with potential for an additional $0.02 per share if reserves permitted. No significant partnerships, acquisitions, funding rounds, or product launches occurred in the last 1-2 years prior to dissolution.
A 10.6% Contrarian Play On Gunlach's Private Credit Hysteria
OTIC Investors Have Opportunity to Join Blue Owl Technology Income Corp. Fraud Investigation with the Schall Law Firm
OTIC Investors Have Opportunity to Join Blue Owl Technology Income Corp. Fraud Investigation with the Schall Law Firm
Why Is Otonomy (OTIC) Stock Up 97% Today?
Best Penny Stocks To Buy? 7 To Watch Under $1 Right Now
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
Otonomy, Inc. (OTIC) CEO Dave Weber on Q2 2022 Results - Earnings Call Transcript
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
Otonomy, Inc. (OTIC) CEO Dr. David Weber on Q1 2022 Results - Earnings Call Transcript
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
Otonomy: Hearing Loss And Tinnitus Data In 2022
Otonomy to Participate in Two Upcoming Investor Conferences
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting
Otonomy to Participate in Two Upcoming Investor Conferences
Otonomy Appoints Jill Broadfoot to Board of Directors
Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update